• LAST PRICE
    3.7672
  • TODAY'S CHANGE (%)
    Trending Down-0.1728 (-4.3858%)
  • Bid / Lots
    3.7600/ 6
  • Ask / Lots
    3.7700/ 6
  • Open / Previous Close
    3.9200 / 3.9400
  • Day Range
    Low 3.7100
    High 3.9200
  • 52 Week Range
    Low 3.7100
    High 14.2200
  • Volume
    821,286
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 3.94
TimeVolumeVSTM
09:32 ET107893.8999
09:34 ET2003.8977
09:36 ET28863.89
09:38 ET42143.87
09:39 ET127883.87
09:41 ET390493.84
09:43 ET36143.85
09:45 ET55183.82
09:48 ET109233.83
09:50 ET26763.8214
09:52 ET203313.84
09:54 ET92583.86
09:56 ET105073.88
09:57 ET33743.86
10:01 ET7603.8402
10:03 ET34363.85
10:06 ET92413.8286
10:08 ET18233.83
10:10 ET17743.8699
10:12 ET6003.85
10:14 ET118673.8495
10:15 ET36393.84
10:17 ET31003.84
10:19 ET20253.86
10:21 ET10833.8586
10:24 ET107783.85
10:26 ET10203.85
10:28 ET93083.85
10:30 ET108053.82
10:32 ET55003.836
10:33 ET82883.81
10:35 ET19003.82
10:37 ET195513.8088
10:39 ET153093.8
10:42 ET237123.805
10:44 ET3473.8098
10:46 ET40033.81
10:48 ET61063.815
10:50 ET33003.8125
10:51 ET19003.81
10:53 ET133843.8
10:55 ET194903.8
10:57 ET379583.74
11:00 ET91073.77
11:02 ET45633.7887
11:04 ET16823.785
11:06 ET28253.79
11:08 ET71783.79
11:09 ET49513.79
11:11 ET24403.79
11:13 ET8003.79
11:15 ET12473.79
11:18 ET3003.79
11:20 ET15503.7807
11:22 ET10003.79
11:24 ET13003.795
11:26 ET95023.7707
11:27 ET134323.75
11:29 ET34833.755
11:31 ET56423.76
11:33 ET37823.75
11:36 ET93603.74
11:38 ET40373.74
11:40 ET23893.75
11:42 ET102443.72
11:44 ET70493.75
11:45 ET32723.7499
11:47 ET74483.75
11:49 ET18073.7614
11:51 ET107793.75
11:54 ET22353.7699
11:56 ET12543.77
11:58 ET37643.7412
12:00 ET50703.75
12:02 ET12453.74
12:03 ET10393.76
12:05 ET76973.75
12:09 ET186533.73
12:12 ET49003.75
12:16 ET293763.74
12:18 ET98233.75
12:20 ET38503.75
12:21 ET11003.7501
12:23 ET16003.7699
12:25 ET42393.745
12:27 ET1003.75
12:30 ET1003.75
12:32 ET52043.755
12:34 ET8003.77
12:36 ET16003.75
12:38 ET360843.74
12:39 ET1593.7412
12:41 ET16743.75
12:43 ET9003.75
12:45 ET1003.75
12:48 ET56663.74
12:50 ET8003.75
12:54 ET138073.75
12:56 ET6653.765
12:57 ET9543.76
12:59 ET3363.765
01:01 ET6163.78
01:03 ET16743.76
01:06 ET119583.77
01:08 ET135373.75
01:12 ET10503.76
01:14 ET8743.7799
01:15 ET8433.7789
01:17 ET4003.77
01:19 ET24803.76
01:21 ET11473.76
01:24 ET26203.76
01:26 ET35003.76
01:28 ET2003.75
01:30 ET18123.76
01:32 ET8483.76
01:33 ET8003.76
01:35 ET1003.765
01:37 ET4003.765
01:39 ET10363.7672
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesVSTM
Verastem Inc
100.3M
-0.9x
---
United StatesATHA
Athira Pharma Inc
100.4M
-0.8x
---
United StatesCNTB
Connect Biopharma Holdings Ltd
98.6M
-1.5x
---
United StatesTLSA
Tiziana Life Sciences Ltd
103.1M
-6.6x
---
United StatesMAIA
Maia Biotechnology Inc
103.7M
-2.5x
---
United StatesYBGJ
Yubo International Biotech Ltd
101.2M
-83.4x
---
As of 2024-06-04

Company Information

Verastem, Inc. is a late-stage development biopharmaceutical company. The Company's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company’s advanced product candidates, avutometinib and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer (CRC), and melanoma. Avutometinib is an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma (RAS)/RAF/MEK, ERK mitogen activated pathway kinase (MAPK) pathway. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2).

Contact Information

Headquarters
117 Kendrick Street, Suite 500CAMBRIDGE, MA, United States 02494
Phone
781-292-4200
Fax
302-655-5049

Executives

President, Chief Executive Officer, Director
Daniel Paterson
Chief Financial Officer
Daniel Calkins
Independent Director
Paul Bunn
Independent Director
Anil Kapur
Independent Director
Michelle Robertson

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$100.3M
Revenue (TTM)
$0.00
Shares Outstanding
25.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.27
EPS
$-4.40
Book Value
$3.11
P/E Ratio
-0.9x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.